Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 2s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Micro Needles Patch for Insulin: Transforming Drug Delivery in Diabetes Management

Yamjala Ganesh Kumar[1], Anitha K N[2*], Amit Verma[3], Sandipkumar Lalit Agrawal[4], Nitin Motiram Gawai[5], Hemant A. Sawarkar [6], Amol Dagdu Landge[7], Lalchand Devhare[8]

[1]Sree Dattha Institute of Pharmacy, Sheriguda, Ibrahimpatnam, Rangareddy district, 501510,Telangana

[2]Government college of Pharmacy, No 2, P KalingaRao Road, Subbaiah Circle, Karnataka, Bangalore – 560027

[3]School of Pharmacy, Chandigarh University Uttar Pradesh, Lucknow-Kanpur Highway - 27, Unnao, Uttar Pradesh, India

[4]Maharashtra College of pharmacy Khamari Gondia MS

[5]Mahadev Kanchan College of Pharmaceutical Education and Research,Mahadev Baugh, BAIF Road, Haveli, Pune, Maharashtra,-412202.

[6]Anuradha College of Pharmacy, Sakegaon Road, Chikhali, Buldhana, 443201

[7]Shram Sadhana Bombay Trust's Institute of Pharmacy Bambhori Jalgaon Maharashtra 425001.

[8]Nagpur College of Pharmacy, Wanadongri, Hingna Road, Nagpur, Maharashtra 441110, India

Corresponding Author

Email ID: knanita@gmail.com

.Cite this paper as: Yamjala Ganesh Kumar, Anitha K N, Amit Verma, Sandipkumar Lalit Agrawal, Nitin Motiram Gawai, Hemant A. Sawarkar, Amol Dagdu Landge, Lalchand Devhare, (2025) Micro Needles Patch for Insulin: Transforming Drug Delivery in Diabetes Management. *Journal of Neonatal Surgery*, 14 (2s), 470-483.

ABSTRACT

A breakthrough in the management of diabetes, micro-needle patches offer a painless and minimally invasive alternative to traditional insulin delivery methods. The patches bypass first-pass metabolism by delivering insulin transdermally directly through the use of micrometer-scale needles that penetrate the outer skin layer. This new approach addresses problems with conventional methods such as variable compliance, needle phobia, and patient discomfort. A very high bio-availability level of up to 98.8% for insulin administered via micro-needles makes it possible to achieve acceptable glycemic control with reduced dosing and reduced frequency. Dissolving and hydro-gel micro-needles with personalized, controlled insulin release are recent developments. By delivering insulin in proportion to blood glucose levels, advanced designs employ glucose-sensitive mechanisms, like hypoxia-sensitive vesicles, to mimic natural pancreas function. Micro-molding and 3D printing are two production methods that enhance precision and scalability, while biodegradable materials ensure safety and reduce the risk of irritation. Clinical trials are equipotent to subcutaneous administration with improved patient compliance, with preclinical testing having demonstrated rapid release of insulin and effective glucose control in animals. Future directions are focused on wearable devices that integrate insulin delivery and glucose monitoring in closed-loop treatment of diabetes. Micro-needle patches hold promise for revolutionizing the treatment of diabetes by increasing the quality of life for patients with painless administration, better glucose control, and greater convenience, if ongoing research is able to overcome regulatory concerns and scale-up manufacturing.

1. INTRODUCTION

Diabetes mellitus

Diabetes mellitus is a global health disorder resulting in elevated blood glucose levels as a result of insufficient insulin production or ineffective insulin use. There are now significantly more individuals affected by this condition, especially in low- and middle-income countries. Diabetes mellitus is a common type of chronic disease characterized as the inability to control blood glucose levels into a normal range.[1-2] Insulin-secreting β-cells are destroyed in type 1 diabetes mellitus (T1DM), an autoimmune disease that causes loss of insulin secretion and abnormal metabolic control. Insulin protects hypoglycemia and hyperglycemia by regulating the metabolism of fats, proteins, and carbohydrates. Providing physiological levels of insulin secretion is the primary challenge of insulin therapy for type 1 diabetes; exogenous insulin cannot successfully deliver to the liver when administered peripherally, nor can it offer feedback regulation. From using insulin obtained from non-human sources to using human-sourced insulin and designed insulin analogues that imitate human insulin activity, pharmaceutical research of insulin therapeutics has advanced. The creation of novel insulin to better treat type 1 diabetes is the main focus of current research in this field.[3] Type 2 diabetes (T2DM) is a metabolic disease that arises from defective insulin secretion, insulin resistance, or both. T2DM accounts for more than 90% of the cases of diabetes and is usually preceded by pre-diabetes, which is associated with an impaired glucose level or increased HbA1c. T2DM is a heterogeneous disease that requires a patient-centric approach for treatment. A true cure will ultimately depend on scientific insight related to its molecular causes, in addition to addressing the obesity epidemic.. [4] According to the IDF (International Diabetes Federation), India has nearly 77 million people between 20-79 years with diabetes already, which is expected to increase to 134.2 million individuals in 2045. The impact of diabetes is more than obvious, with > 1 million deaths in India attributable to diabetes and its complications[5]



Fig. 1.1: Mechanism of Insulin in healthy and diabetic patients

Conventional therapies used in diabetes mellitus

1. Oral dosage forms such as metformin, glimepiride, sitaglipitin are commonly used for type 2 diabetes .they also include immediate release, extended release and combination formulations.[6]
2. Injectable like subcutaneous injections are predominantly used for insulin delivery, encompassing rapid-acting, short –acting, intermediate acting and long acting insulin.
3. Inhalable insulin designed for rapid absorption of insulin via lungs offering an alternative to injections. [7]
4. Insulin pumps provide continuous subcutaneous insulin infusion, closely mimicking physiological insulin release.[8]

Challenges in traditional insulin delivery

Conventional delivery approaches to insulin have several important limitations that impact patient compliance and general glycemic control. The following are the main issues:

1. Pain and Distress.

The most widely used route of insulin delivery, subcutaneous injection, frequently is painful at the injection site. This pain may discourage patients from following their prescribed insulin treatment, particularly those who need multiple daily injections.[9-10]

2. Variable Compliance.

The daily injection hassle is one reason for variable patient compliance. It is difficult for many patients to keep a regular injection schedule, an important factor in successful diabetes control.[9,7]

3. Risk of Hypoglycemia.

Intensive insulin treatment may result in an elevated risk for hypoglycemic events, especially with the use of more than one dose over the course of the day. The risk hinders attempts at tight glycemic control and may lead to patient anxiety.[9,10]

4. Psychological Barriers.

Psychological insulin resistance is also prevalent, whereby patients might not want to start or comply with insulin therapy because of concerns regarding side effects, lifestyle modifications, or societal stigmatization of insulin use.[7]

5. Restrictive Features of Existing Devices.

Though developments such as insulin pens and pumps have enhanced convenience, they are still subject to periodic maintenance and can be resource-intensive. Insulin pumps, for example, are pricey and potentially unavailable to all patients.[10,7]

6. Inadequate Convenience of Alternatives.

While alternative routes of delivery like inhaled insulin and jet injectors have been investigated, several have encountered efficacy and patient acceptance issues. For instance, inhaled insulin was taken off the market because of low rates of use.[7,11]

7. Physiological Limitations.

Existing delivery modalities fail to closely simulate physiologic insulin release from the pancreas and result in side effects such as peripheral hyper-insulinemia. This disparity will make postprandial control of blood glucose more difficult.[9,10]

Need of advanced drug delivery system such as micro-needle

The demand for sophisticated drug delivery systems, including insulin micro needles patches, stems from a number of key issues concerning the control of diabetes and the short comings of conventional delivery systems.

1. **Avoidance of First-Pass Metabolism**: One of the major benefits of employing micro-needles is that they avoid the hepatic first-pass metabolism of orally administered drugs. This leads to improved bio-availability and enables reduced doses to be effective with the same therapeutic outcomes as oral drugs.[12,13]

2. **Minimally Invasive Delivery**: Micro-needle (MN) technology enables the pain-free puncture of the skin, without piercing the stratum corneum, which is a major barrier in trans-dermal drug administration. It reduces discomfort from conventional subcutaneous injection and is thus preferable to patients[,13]

3. **Controlled and Sustained Release** : Insulin micro-needle patches may be formulated to deliver controlled and sustained release of insulin, enhancing glycemic control in diabetic patients. The drug loading flexibility enables accurate dosing according to individual patient requirements.[13]

4. **Improved Drug Stability:**The formulation utilized in micro-needle patches is able to shield sensitive drugs such as insulin from degradation. Dissolving micro-needles, for instance, can encapsulate insulin within a biodegradable polymer matrix that keeps it stable until the time of administration. [13]

2. MICRO-NEEDLE IN DRUG DELIVERY SYSTEM : A REVOLUTIONARY APPROACH

A micro-needle drug delivery system can therefore be described as a novel drug delivery system approach in which the drug is delivered into the systemic circulation through the needles. The general reaction to micro-needles is based on the idea that they can disrupt the stratum corneum layer of skin, which can result in a smooth pathway for the entry of desired molecules. The system in which micron-sized needles pierce the superficial layer of the skin and diffuses the drug across the epidermis layer which is then passed on into the blood capillary region for active absorption as micro needles are short and thin they help in avoiding the pain caused to patient . This could be achieved by Micro fabrication technology.[14]

Principle

Mechanism of Action: Micro-needles create micro-punctures in the skin, allowing for the transport of drugs into the epidermis or upper dermis. This bypasses the skin's barrier function, which typically limits drug absorption through traditional trans-dermal methods. [15]

Types of Micro needles

Micro-needles are tiny needles used for various applications, primarily in drug delivery and diagnostics. There are five main types of micro-needles, each with distinct characteristics and uses:

1. **Solid Micro-needles**: These needles puncture the skin to create micro incisions, allowing drug solutions to seep into the skin. They are easy to manufacture but can lead to infections if not properly managed. Commonly used for drug delivery and cosmetic applications.[16]
2. **CoatedMicro-needles:** These have a drug coating that dissolves once inserted into the skin, allowing the drug to be absorbed. They simplify the application process but have limitations on the amount of drug they can deliver due to the thin coating.[17]
3. **HollowMicro-needles**: These needles contain a hollow channel that allows for direct drug delivery from a reservoir.

They can deliver larger doses but may face issues like leakage and clogging. They are often used in disease diagnostic.[18]

4. **DissolvableMicro-needles**: Made from materials like sugar or polymers, these needles dissolve in the skin after insertion, releasing their drug payload. They are beneficial for vaccine delivery and cosmetic treatments but can be more complex to manufacture. [16]

5. **Hydro-gel-FormingMicro-needles**: These swell upon contact with bodily fluids which leads to rapid formation of hydro-gel facilitating drug release. Unlike dissolvable micro-needles, they remain in place until removed along with the patch. They are suitable for delivering hydrophilic drugs .[15]

Table 1.1 : Overview of types of micro needles [15]

MN Type	Characteristics	Advantages	Disadvantages	Application	Material
Solid MNs	Creates channels in the skin to allow drugs reach the lower skin layer. Adequate mechanical strength. Sharper tips.	Allow more drugs to pass into the skin. Easy to manufacture	Damage to the skin and micro incisions need to be closed to avoid infections.	Drug delivery. Cosmetics.	Silicon, Metal, Polymer
Hollow MNs	Empty shape to be filled with the drug. Ability to control drug release over time.	Handles a large dose/amount of drug solution.	Weak needles. Requires intensive care in terms of needle design and insertion method. Might cause leakage and clogging.	Disease diagnosis.	Silicon
Coated MN s	Carries less amount of the drug due to the design. Ability to deliver the proteins and DNA in a minimally invasive manner.	Deliver the drug quickly to the skin.	Prone to infection.	Drug delivery. Vaccine delivery.	Silicon
Dissolv ing MNs	Facilitates rapid release of macro molecules.	Ease of administration for patients with one step application.	Requires technical expertise to manufacture. Takes time to dissolve.	Drug delivery. Cosmetics. Vaccine delivery.	Polymer

Working of micro-needle:-

The mechanismof actiondepends onthe typeof micro-needle design. The drugis entrappedwithin the micro-needles, which when inserted into the skin and releases the drug into the layers of skin which are highly vascular zed. In some cases, the needles dissolve within minutes, releasing the entrappeddrug atthe intendedsite ofdelivery fromwhere theyreach thetarget site . micro-needles can either be pressed ontothe skin or scraped onthe skin for creating microscopicholes, therebyincreasing skin permeability by up to four orders of magnitude. This coating can dissolvewithin 1min afterinsertion intoskin, after which the micro-needles can be withdrawn and discarde. MNs have been proposed as a mechanism for adjuvant hair re-growth in alopecia. The efficacyof MNin bothandrogentic alopecia (AGA) and has beenhighlighted over the last 5 years Derma roller treatment combined with 5% minoxidil lotion was administered to half of the participants, with 80% showing moderately or greatly increased hair re-growth per the investigators . Generally, MNs patches or substrates possess similar basic design elements such as an ordered array of MNs ranging from a few to a few hundred in number. MNs areprepared fromvarious materials and manufactured in a plethora of shapes and sizes.[19]

Fabrication of MNs :

These techniquesare usedin isolation orcombination tocreate implantablebiomedical devices. Typically microfabricated implantsare developedin siliconor similarmaterials, dueto easeof manufacturing. After proof of concept has been shown, the implant can then be modified to be cast in additional materials through techniques such as micro-molding . Micro-molding isthe most common fabrication technique for MNs. In this technique, negativeelastomeric poly-di-methyl-siloxane (PDMS) molds are used for polymer casting to prepare MNs.[19]

Table 1.2 : Fabrication methods of micro - needles[19]

Sr.no.	Methods of Fabrication	Types of micro - needles produced
1.	Laser cutting	Metallic
2.	Laser ablation	Metallic
3.	Vapour deposition	Silicon
4.	Dry etching	Silicon, Hollow type
5.	Wet etching	Silicon, metallic
6.	Micro - molding and melt casting	Dissolvable/Hydro - gel forming, Ceramic
7.	Micro - stereo lithography	Silicon, Metallic
8.	Metal electroplating	Metallic, Hollow type
9.	Photo lithography	Dissolvable/Hydro - gel forming, hollow type
10.	Dipping	Coated type
11.	Continuous liquid interface production (CLIP)	Coated type

3. OBJECTIVE OF MICRO NEEDLES

1. **Minimally Invasive Delivery: Micro-needles** create micro-sized pores in the skin without reaching nerve endings, thus significantly reducing pain compared to traditional hypodermic needles.

2. **Enhanced Drug Delivery:** They allow for the trans-dermal delivery of a wide range of low molecular weight drugs, bio-therapeutics, and vaccines. This method bypasses the skin's barrier properties, making it effective for various applications including vaccinations and treatments for chronic diseases.

3. **Versatile Applications:** Beyond drug delivery, micro-needles are also used in cosmetic procedures, such as collagen induction therapy, and for diagnostic purposes. They can be designed in various forms—solid, hollow, coated, or dissolving—each serving different functions depending on the therapeutic needs.

4. **Patient Compliance:** The design aims to improve patient compliance by reducing the fear and discomfort

associated with injections. Micro-needle patches can be self-administered, making them convenient for patients who may have difficulty with traditional methods.[20,15]

4. MICRO-NEEDLE PATCH FOR INSULIN THERAPY IN DIABETES

MNs are capable of enhancing the compliance of patients and patients can also self-administer. This isan excellent potential as a substitute for conventional insulin therapy. Hollow MNs are indirect auxiliary administration, whereby hydro-gel and dissolving MN can be directly filled with insulin for administration, and both can significantly enhance the quantity of insulin trans-dermal delivery. Furthermore, glucose-responsive MNs can actually deliver exact insulin dosage tailored to the individual's blood level in real-time.[13]

Mechanism of action of micro-needle in insulin delivery

Micro needles are tiny, minimally invasive devices that penetrate the skin's outer layer, or stratum corneum. They form micro channels, through which insulin can directly be injected into the dermis, where it gets absorbed into the blood. The micro needles degrade fast on insertion, releasing the insulin payload. Substances such as starch and gelatin are typically employed due to their bio-compatibility and quick dissolution in the interstitial fluid of the skin, thus providing effective and effective insulin delivery.[21.]

Micro-needle devices mechanisms that respond to glucose are incorporated to increase the delivery of insulin according to current blood glucose concentration. One example is the employment of hypoxia-sensitive vesicles. Such vesicles would release insulin if blood glucose is elevated. The idea behind such a mechanism is to replicate the natural operation of the pancreas, which delivers insulin when blood glucose is elevated. Hypoxia-sensitive vesicles are responsive to fluctuations in the body's oxygen levels, which are related to high blood glucose. When blood glucose is high, the vesicles chemically change, causing insulin release directly at the point of action. This glucose-sensitive technology would have the potential to much better regulate blood glucose levels, lessening the risk of both hyperglycemia and hypoglycemia. The micro-needles contain vesicles that are sensitive to low oxygen levels. When glucose is metabolized in the area, it creates a hypoxic (low oxygen) environment. This triggers the vesicles to release insulin in a controlled manner, ensuring that insulin is delivered when necessary based on the local oxygen levels.[22]



Fig 1.2.: Mechanism of drug release through micro – needles

Advantages of micro-needles for insulin delivery

1. Micro-needle patches are made to pierce the skin's dermal layer without inducing pain or blood loss, rendering them more tolerable than conventional needles .The small nature and structure of the micro-needles guarantee that they are less threatening and more acceptable to the users, thereby possibly enhancing adherence to insulin treatment.

2. The micro-needle patch employs a graphene-based bio-sensor to measure glucose levels and initiate release of insulin, and an electroosmotic micro-pump provides controlled, stable insulin infusion for long-term glucose regulation.[23]

3. Microneedles deliver insulin with around 98.8% bio-availability, much higher than injections or oral administration. By directly delivering insulin into the skin, they bypass the liver's first-pass metabolism, preserving its potency. This leads to more effective glucose control with smaller doses and less frequent administration.

4. Micro-needle structures of different forms, including hydro-gel and

dissolving ones, enable customized profiles of insulin release to cater to varying dietary needs. Innovations such as thermosensitive micro-needles allow for insulin delivery based on blood glucose levels, offering a responsive treatment solution.[24]

5. RECENT ADVANCES

1. **Biodegradable Polymers:-**Biodegradable polymer-based micro-needles are increasingly favored due to their bio-compatibility, cost-effectiveness, and ability to dissolve or degrade within the skin after delivering drug.

2. **Material Innovations:-** Polymers such as poly-lactic acid (PLA), poly lactic-co-glycolic acid (PLGA), and polyvinylpyrrolidone (PVP) are commonly used due to their mechanical strength and controlled degradation properties.[25,26]

3. **3D Printing Techniques:-** Fused deposition modeling (FDM) has enabled precise fabrication of micro-needles with customizable shapes, sizes, and densities. Post-fabrication chemical etching allows tip sizes as small as 1 µm, enhancing penetration and drug release efficiency.

4. **Metal-Based Micro-needles:-**Metal micro-needles are valued for their mechanical strength, durability, and bio-compatibility. Stainless steel and titanium are the most widely used metals due to their robustness and compatibility with biological tissues. Other metals like nickel and palladium are also being explored for specific applications.

5. **Applications:-** Metal micro-needles are particularly suitable for applications requiring high mechanical strength, such as vaccine delivery or cancer therapy. They offer precise control over dosage and rapid onset of action.

6. **MarketGrowth:-** Metal micro-needles accounted for a significant revenue share in the global market in 2024, reflecting their widespread adoption in clinical practices.[26]

6. PRECLINICAL AND CLINICAL STUDIES

Preclinical studies

The study of ming –hung et.al confirms that insulin-loaded starch/gelatin micro-needles show a fast and complete drug release profile upon insertion into porcine cadaver skin. Within just 4 minutes, nearly all the entrapped insulin was released at a consistent rate, reflecting the effective drug delivery potential of these micro-needles. The micro-needles also dissolved in 5 minutes completely after being inserted, another confirmation of the potential of micro-needles as a effective and quick delivery system. Such findings suggest that starch/gelatin micro-needles are a potential contender for rapid-acting insulin delivery in a clinical setting.[21]

Wijaya Martanto et .al, in their research indicates that micro-needles were effective in delivering insulin through the skin in diabetic rats, which caused considerable lowering of blood glucose. Briefer microneedle insertion periods (i.e., 10 seconds) prior to insulin delivery were superior to longer times. Multiple insertions, though, reduced insulin delivery efficacy because of skin injury. In conclusion, micro-needles are a promising non-invasive route for controlled insulin delivery, and the best outcome resulted from brief insertion times[27]

Clinical studies

Micro-needles facilitate a non-invasive method for insulin delivery, significantly reducing pain and anxiety associated with traditional hypodermic injections. Clinical studies have shown that these patches can deliver insulin effectively, with pharmacological availability comparable to subcutaneous injections [28]

Safety and efficacy of micro-needle patch of insulin

Micro-needles induce very small punctures in the skin that heal very quickly, generally within 90 minutes, which restores the skin's barrier function, e.g., transepidermal water loss (TEWL), to normal. This suggests little disruption to the skin. The therapy has no substantial inflammation or tissue damage in the skin, liver, kidneys, or spleen of treated diabetic rats, pointing to its safety. In diabetic rats, in which healing is normally slower, the absence of inflammation or injury indicates that micro-needling is tolerable and appropriate for patients with compromised healing. In general, micro-needling provides a minimally invasive, safe, and effective treatment for skin procedures with less recovery time.[29,30]

Biodegradable materials such as polyvinyl alcohol and hyaluronic acid are also favored in micro-needle (MN) production due to their in-noxious dissolution in interstitial fluid, minimizing irritation and complications risks. Clinical-grade micro-needle devices, such as Micron-jet, are tested with bio-compatibility tests reporting minimal cytotoxicity and irritation. The findings indicate that micro-needles are safe, efficient, and appropriate for medical and cosmetic uses in diverse applications[30,23]

Table 1.3 Comparative studies with conventional method:[31,32,33,13]

FEATURES	TRADITIONAL INSULIN DELIVERY (INHALABLE/ INJECTABLE)	MICRO NEEDLE PATCH FOR INSULIN DELIVERY
METHOD OF DELIVERY	Insulin is delivered through a syringe, pen, or a device that an individual inhales.	Insulin is administered via tiny, painless micro needles in the patch.
NEEDLE INSERTION	Requires a needle for injection.	Uses micro-needles, that are small, minimally invasive, and normally painless
FREQUENCY OF ADMINISTRATION	Multiple injections throughout the day or continuous infusion through an insulin pump.	Either worn for long periods as a patch, releasing insulin slowly.
PAIN LEVEL	Injection is painful and can be uncomfortable, particularly for people with needle phobia.	Micro-needles are very invasive and inflict minor to no pain.
EASE OF USE	It requires one to administer appropriately, especially with self -injection.	Simple to use, as it is a matter of applying a patch to the skin without the necessity for manual injections.
FLEXIBILITY	Insulin shots are very flexible, yet demanding of precise scheduling.	Patches can be more flexible, but dosage and timing can be more regulated.
DOSAGE CONTROL	Instant control over the dose during each injection.	Sustained and steady release, but could be precise in patch design.
SKIN IRRITATION	Provides high accuracy with each dose administered.	Micro-needles are made to be less irritating, but long-term use can still lead to skin reactions.
PORTABILITY	.May result in irritation or scar tissue due to repeated injections.	Micro-needle patches are discreet and can be worn under clothes
ACCURACY & CONSISTENCY	Insulin pumps or pens are convenient but in some way, inconvenient.	Offering more reliable release over time but can vary depending on patch design.
TRAINING REQUIREMENTS	Requires training to administer insulin properly.	No specific training required, easy application such as patch wearing.
SIDE EFFECTS	Risk of hypoglycemia when dosing is inappropriate; reactions at the injection site.	Less side effects; risk of irritation or allergic reaction to patch material

7. REGULATORY CONSIDERATION

Regulatory aspects for micro-needle insulin patches are essential because they are innovative products with the potential to significantly affect diabetes treatment. The following are the main areas that must be considered:

Safety and Efficacy Requirements

1.Bio-compatibility: Micro-needles have to be tested extensively for bio-compatibility. Tests for cytotoxicity, sensitization, irritation, and systemic toxicity are conducted depending on how long the skin is in contact with them.[30]]

2. Sterility : Since micro-needles puncture the skin, sterility becomes of critical importance to avoid infection. Regulatory agencies usually demand terminal sterilization of these products to guarantee safety, particularly for diabetic patients who are more susceptible to infections .[28]

3 . Pharmacokinetics and Pharmacodynamics: Extensive research has to be done to examine the release of insulin from micro-needles into the bloodstream and the resulting impact on blood glucose. The studies assist in the determination of dosing regimens and safety profiles.[13]

Manufacturing Standards

Good Manufacturing Practices (GMP) compliance is necessary for the manufacture of micro-needle insulin patches. This involves maintaining consistent product quality, sterility, and safety standards throughout the manufacturing process.[34,28]

Regulatory Pathways and Challenges

The regulatory route for micro-needle devices is intricate because there are no standardized guidelines specifically for such systems. Every application could call for separate clearance, making it difficult to enter the market with new micro-needle technologies. Clinical studies are currently being conducted to evaluate the safety and efficacy of these devices in human subjects, and these findings will impact future regulation.[35]

Long-term Considerations

Long-term evaluations are required to assess possible unwanted effects from cumulative use of micro-needles, such as skin reactions or systemic problems from polymer residues on the skin. User experience concerning ease of handling and consistency in administration is also important to make diabetes control efficient.[34]

8. FUTURE PROSPECTS FOR MICRO-NEEDLE INSULIN PATCHES

Future prospects for micro-needle insulin patches look good, fancements and growing demand for non-invasive diabetes care solutions. Following are some developments and trends that are defining the scenario:-

Technological Advances

1. **Wearable Systems** : A recent study introduced a wearable micro-needle patch that consists of a graphene composite ink-printed sensor and an electrosmotic micro-pump. The system promotes stability and enables accurate glucose monitoring and insulin delivery, showing successful blood glucose control in animal models. These technologies may transform closed-loop diabetes control systems to be more available and efficient for patients.[23]
2. **Micro-needle Designs Diversity** : Micro-needle designs with hollow, dissolving, and hydro-gel-forming types are under investigation. These types of designs are designed to maximize insulin delivery via the skin while minimizing invasiveness. An example is the hollow micro-needle, which demonstrates promising pharmacokinetic profiles that are equivalent to the standard subcutaneous injections, suggesting potential for broad clinical application.[30,37]

Clinical Trail and Research:

Ongoing Clinical Evaluations: Various micro-needle products are in ongoing clinical trials to evaluate their effectiveness and safety for insulin delivery. These trials are important for learning about the real-world utility of these technologies as well as to overcome regulatory issues that have delayed development in the past.[35]

Increased Bio-availability:

Research shows micro-needle systems are able to have a similar bio-availability as conventional subcutaneous injections. As an instance, one research proved that insulin was delivered via a micro-needle patch with a relative pharmacological availability greater than in standard injections. This indicates that delivery of insulin might be more efficient with micro-needles.[30]

Market Trends and Challenges

Commercialization Initiatives: The commercial market for micro-needle drug delivery systems is growing, driven by interest from researchers and pharmaceutical firms. Successful commercialization will, however, rely on overcoming issues of manufacturing scalability, regulatory approval procedures, and patient safety[35,36]

Personalized Medicine

: Digital twin technology advancements could enable the tailoring of micro-needle patches to the unique needs of individual patients. Personalized treatment could improve outcomes by optimizing insulin delivery according to individual patient characteristics.[35]

9. IMPACT OF MICRO-NEEDLE TECHNOLOGY ON DIABETES TREATMENT AND PATIENT'S QUALITY OF LIFE MICRO-NEEDLE

Insulin patches have the potential to revolutionize diabetes management by offering a painless and more convenient alternative to traditional insulin injections. Studies have shown that micro-needles, which penetrate the skin minimally, significantly reduce pain compared to conventional syringes [53]

Additionally, these patches provide a discreet and user-friendly option, allowing patients to administer insulin without drawing attention, making diabetes management more seamless in daily life. Beyond convenience, micro-needle patches contribute to better blood glucose regulation[22,13].

This patches offers more patient friendly and less invasive alternative which lowers the blood glucose levels by mimicking the body's natural insulin regulation. Hence potentially improving adherence and overall quality of life for individuals with diabetes[39-95].

10. CONCLUSION

Micro-needle patches are a revolutionary development in the management of diabetes, providing a painless, efficient, and patient-friendly solution to conventional insulin delivery. Micro-needle patches use micrometer-scale needles to pierce the outer skin layer without pain, allowing controlled and sustained delivery of insulin directly into the circulatory system. By avoiding first-pass metabolism, micro-needles increase bio-availability and lower dosing requirements, enhancing glycemic control while decreasing risks of hypoglycemia.

Recent technologies, such as glucose-sensitive micro-needles with on-board bio-sensors, enable real-time insulin delivery customized to the blood glucose concentration. This device emulates the pancreas's natural function, providing dynamic and smart diabetes care. In addition, bio-compatible materials and novel fabrication methods such as 3D printing have enhanced micro-needle safety, effectiveness, and scalability.

Preclinical and clinical trials have shown similar pharmacologic availability to subcutaneous injections but also reduce pain and psychological hurdles compared to conventional techniques. The patches also bypass the problem of patient compliance by facilitating self-administration without professional training.

Despite challenges like regulatory obstacles and scalability of manufacturing, micro-needle patches are ready to transform the management of diabetes. Their potential to effectively deliver insulin while making it more convenient and easier for patients to stick to treatment represents a major improvement in the quality of life of people with diabetes.

REFERENCES

[1] DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2015 Jul;7(4):548-64.

[2] Suryasa IW, Rodríguez-Gámez M, Koldoris T. Health and treatment of diabetes mellitus. International journal of health sciences. 2021;5(1):572192.

[3] Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology. 2017 Jul;13(7):385-99.

[4] DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC. Type 2 diabetes mellitus. Nature reviews Disease primers. 2015 Jul 23;1(1):1-22.

[5] Muralidharan S. Diabetes and current Indian scenario: a narrative review. Journal of Diabetology. 2024 Jan 1;15(1):12-7.

[6] Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral anti-diabetic drugs. Expert opinion on drug safety. 2013 Mar 1;12(2):153-75.

[7] Akhrass F, Skinner N, Boswell K, Travis LB. Evolving trends in insulin delivery in pursuit of improvements in diabetes management. American Health & Drug Benefits. 2010 Mar;3(2):117.

[8] Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy. Diabetes spectrum: a publication of the American Diabetes Association. 2019 Aug;32(3):194.

[9] Shah RB, Patel M, Maahs DM, Shah VN. Insulin delivery methods: Past, present and future. International journal of pharmaceutical investigation. 2016 Jan;6(1):1.

[10] Al-Tabakha MM, Arida AI. Recent challenges in insulin delivery systems: a review. Indian journal of pharmaceutical sciences. 2008 May;70(3):278.

[11] https://www.news-medical.net/health/Bionic-Advancements-The-Next-Generation-of-Insulin-Delivery-Devices.aspx viewed 30 march 2025

[12] Munjavarapu.J,yerramsetti . P.review on micro-needle patches for drug delivery and vaccine delivery. 2024 August ; Vol 2, Issue 8, 2487-2503

[13] Zhao J, Xu G, Yao X, Zhou H, Lyu B, Pei S, Wen P. Micro-needle based insulin transdermal delivery system: current status and translation challenges. Drug Delivery and Translational Research. 2022 Oct 1:1-25.

[14] Agrawal S, Gandhi SN, Gurjar P, Saraswathy N. Micro-needles: An advancement to transdermal drug delivery system approach. Journal of Applied Pharmaceutical Science. 2020 Mar 5;10(3):149-59.

[15] Aldawood FK, Andar A, Desai S. A comprehensive review of micro-needles: Types, materials, processes, characterizations and applications. Polymers. 2021 Aug 22;13(16):2815

[16] .Jacoby E, Jarrahian C, Hull HF, Zehrung D. Opportunities and challenges in delivering influenza vaccine by micro-needle patch. Vaccine. 2015 Sep 8;33(37):4699-704.

[17] Kwon KM, Lim SM, Choi S, Kim DH, Jin HE, Jee G, Hong KJ, Kim JY. Micro-needles: quick and easy delivery methods of vaccines. Clinical and experimental vaccine research. 2017 Jul 1;6(2):156-9

[18] Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, Dua K. Micro-needles: A smart approach and increasing potential for transdermal drug delivery system. Biomedicine & pharmacotherapy. 2019 Jan 1;109:1249-58

[19] Borey VS, Ingle SB, Kotwal PV, Jadhao AG, Sheikh TR, Nagrik SU, Sanap JB. A review Recent Advanced of Fabrication Techniques and Application of Micro-Needle. Asian Journal of Pharmaceutical Research and Development. 2023 Jun 15;11(3):59-66.

[20] Kim YC, Park JH, Prausnitz MR. Micro-needles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012 Nov;64(14):1547-68. doi: 10.1016/j.addr.2012.04.005. Epub 2012 May 1. PMID: 22575858; PMCID: PMC3419303

[21] Ling MH, Chen MC. Dissolving polymer micro-needle patches for rapid and efficient transdermal delivery of insulin to diabetic rats. Acta biomaterialia. 2013 Nov 1;9(11):8952-61.

[22] Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, Ligler FS, Buse JB, Gu Z. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proceedings of the National Academy of Sciences. 2015 Jul 7;112(27):8260-5.

[23] Liu Y, Yang L, Cui Y. A wearable, rapidly manufacturable, stability-enhancing micro-needle patch for closed-loop diabetes management. Microsystems & nanoengineering. 2024 Aug 19;10(1):112.

[24] Maia M, Jesus S, Borges O. OPTIMIZING INSULIN THERAPY: ARE MICRONEEDLES A VIABLE ALTERNATIVE TO SUBCUTANEOUS INSULIN INJECTION?. Journal of Drug Delivery Science and Technology. 2024 Sep 24:106229.

[25] Gera AK, Burra RK. The Rise of Polymeric Micro-needles: Recent Developments, Advances, Challenges, and Applications with Regard to Transdermal Drug Delivery. J FunctBiomater. 2022 Jun 15;13(2):81. doi: 10.3390/jfb13020081. PMID: 35735936; PMCID: PMC9224958

[26] Luzuriaga MA, Berry DR, Reagan JC, Smaldone RA, Gassensmith JJ. Biodegradable 3D printed polymer micro-needles for transdermal drug delivery. Lab on a Chip. 2018;18(8):1223-30.)

[27] Martanto W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR. Transdermal delivery of insulin using micro-needles in vivo. Pharmaceutical research. 2004 Jun;21:947-52.

[28] Smith F, Sabri AH, Heppel M, Fonseca I, Chowdhury F, Cheung K, Willmor S, Rawson F, Marlow M. The clinical and translational prospects of micro-needle devices, with a focus on insulin therapy for diabetes mellitus as a case study. International journal of pharmaceutics. 2022 Nov 25;628:122234.

[29] Yang J, Li Y, Ye R, Zheng Y, Li X, Chen Y, Xie X, Jiang L. Smartphone-powered iontophoresis-microneedle array patch for controlled transdermal delivery. Microsystems & nanoengineering. 2020 Dec 28;6(1):112.

[30] Avcil M, Çelik A. Micro-needles in drug delivery: progress and challenges. Micromachines. 2021 Oct 28;12(11):1321.

[31] Pittas AG, Balk EM. Untangling the Gordian knot of vitamin D supplementation and type 2 diabetes prevention. Diabetes care. 2020 Jun 11;43(7):1375.

[32] Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978 Jan 28;1(6107):204-7. doi: 10.1136/bmj.1.6107.204. PMID: 340000; PMCID: PMC1602534.

[33] Patel S, Kim J, Herrera M, Mukherjee A, Kabanov AV, Sahay G. Brief update on endocytosis of nanomedicines. Advanced drug delivery reviews. 2019 Apr 1;144:90-111.

[34] Meng F, Qiao X, Xin C, Ju X, He M. Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery. Journal of Pharmacy & Pharmaceutical Sciences. 2024 Mar 20;27:12434.

[35] https://www.tcs.com/what-we-do/industries/life-sciences/white-paper/emerging-trends-microneedles-insulin-delivery.html viewed 28 march 2024

[36] Jana BA, Wadhwani AD. Micro-needle–Future prospect for efficient drug delivery in diabetes management. Indian journal of pharmacology. 2019 Jan 1;51(1):4-10.

[37] Turner JG, White LR, Estrela P, Leese HS. Hydro-gel-forming micro-needles: current advancements and future trends. Macro molecular Bioscience. 2021 Feb;21(2):2000307.

[38] https://en.m.wikipedia.org/wiki/Microneedles viewed 29 march 2024

[39] Salpe, H. G., Devhare, L. D., Ghugare, A. P., & Singh, N. (2016). Formulation and evaluation of hpmc coated diltiazem hcl tablet and its comparison with other marketed preparation. Research chronicle in health sciences, 3(1), 11-17.

[40] Devhare, L., Hiradeve, S., & Bobade, T. (2017). Method Development & Validation For Determination Of Water Content. LAP LAMBERT Academic Publishing.

[41] Devhare, L. D., Ghugare, A. P., Hatwar, B. P., Goupale, D. C., & Devhare, L. D. (2015). Method development for determination of water content from various materials by spectrophotometry and it's validation. International journal of drug delivery, 7(4), 233-240.

[42] Tonde, T. U., Kasliwal, R. H., & Devhare, L. D. (2016). Quantitative estimation of bacoside a in polyherbal memory enhancer syrup for memory boosting activity using hptlc method. Research chronicle in health sciences, 2(6), 315-320.

[43] Devhare, L., & Kore, P. K. (2016). A recent review on bioavailability and solubility enhancement of poorly soluble drugs by physical and chemical modifications. Research chronicle in health sciences, 2(5), 299-308.

[44] Ghugare, A. P., Devhare, L., & Hatwar, B. P. (2016). Development and validation of analytical methods for the simultaneous estimation of Nimorazole and Ofloxacin in tablet dosage form. International Journal of Drug Delivery, 8, 96-98

[45] Makhani, A. A., & Devhare, L. (2017). Development and validation of vierordt's spectrophotometric method for simultaneous estimation of Drotaverine and Nimesulide combination. Research chronicle in health sciences, 3(2), 22-28

[46] Makhani, A. A., & Devhare, L. D. (2017). Development and validation of analytical methods for drotaverine and nimesulide combination. Research chronicle in health sciences, 3(3), 40-44.

[47] Katole, G., & Devhare, L. (2018). Diluent and granulation study on Metformin Hydrochoride. LAP LAMBERT Academic Publishing.

[48] Katole, G., & Devhare, L. D. (2020). Recent insight into some emerging natural resources with remarkable hepato protective potentials. International journal of pharmaceutical science and research, 5(1), 41-47.

[49] Devhare, L. D., & Gokhale, N. (2021). Acid neutralizing capacity and antimicrobial potential of selected solvent extract from various indigenous plants. Journal of Advanced Scientific Research, 12(04), 175-179

[50] Uplanchiwar, V. P., Raut, S. Y., & Devhare, L. D. (2021). Pharmacological assessment of antiulcer activity of gloriosa superba linn tubers in experimentally induced gastric ulcers. Journal of medical pharmaceutical and allied science, 10(3), 2852-2856.

[51] Devhare, L. D., & Gokhale, N. (2022). Antioxidant and Antiulcer property of different solvent extracts of Cassia tora Linn. Research journal of pharmacy and technology, 15(3), 1109-1113.

[52] Devhare, L. D., & Gokhale, N. (2023). A brief review on: phytochemical and antiulcer properties of plants (fabaceae family) used by tribal people of gadchiroli maharashtra. International journal of pharmaceutical sciences and research, 14(4), 1572-1593.

[53] Devhare, L. D., & Gokhale, N. (2023). In silico anti-ulcerative activity evaluation of some bioactive compound from Cassia tora and Butea monosperma through moleculer docking approach. International journal of pharmaceutical sciences and research, 14(2), 1000-08.

[54] Suruse, P. B., Jadhav, B. A., Barde, L. G., Devhare, L. D., Singh, S., Minj, K. H., & Suman, A. (2023). Exploring the potential of Aerva Lanata extract in a herbal ointment for fungal infection treatment. Journal of Survey in Fisheries Sciences, 10(1), 1922-1932.

[55] Bodhankar, S. S., Devhare, L. D., Meshram, A. S., Moharkar, D. W., & Badwaik, C. B. (2023). Formulation and in vitro evaluation of dental gel containing ethanglic extract of Mimosa pudica. European Chemical Bulletin, 12(5), 1293-1299.

[56] Shende, S. M., Bhandare, P., & Devhare, L. (2023). In-vitro: micropropagation of mint and investigate the antibacterial activity of mint extract. Eur. Chem. Bull, 12(5), 780-784.

[57] Singh, S., Minj, K. H., Devhare, L. D., Uppalwar, S. V., Anand, S., Suman, A., & Devhare, D. L. (2023). An update on morphology, mechanism, lethality, and management of dhatura poisoning. Eur. Chem. Bull, 12(5), 3418-3426.

[58] Devhare, L. D., Bodhankar, S. S., Warambhe, P., Uppalwar, S. V., Devhare, D. L., Uchibagle, S., & Shende, S. (2023). Important role of food and nutritional security during Covid-19: A survey. Eur. Chem. Bull, 12(5), 1363-1374.

[59] Gnana, R. P. M., Devhare, L. D., Dharmamoorthy, G., Khairnar, M. V., & Prasidha, R. (2023). Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance, 14(3), 475-480.

[60] Prasad, M., Suman, A., Srivastava, S., & Devhare, L. D. (2023). Butea monosperma stem bark extract partially reverses high fat diet-induced obesity in rats. Eur. Chem. Bull, 12(5), 4267-4273.

[61] Thakare, V. M., Umare, S. A., & Devhare, L. D. (2023). Separation and purification of carboxymethyl cellulose from Spinacia Oleracea for use in pharmaceutical dosage form. Eur. Chem. Bull, 12(5), 4062-4080.

[62] Suruse, P. B., Deshmukh, A. P., Barde, L. G., Devhare, L. D., Maurya, V. K., Deva, V., & Priya, N. S. (2023). Rimegepant embedded fast dissolving films: A novel approach for enhanced migraine relief. Journal of Survey in Fisheries Sciences,10(1), 2071-2084.

[63] Pathak, N. R., Devhare, L. D., Sawarkar, K. R., Dubey, M., Trivedi, V., Thakre, A. R., & Thakare, V. M. (2023). Aclinial reveiew on pharmacological evaluation of Thiazolidine and Isatin in the new millenium as magic moieties. Eur. Chem. Bull, 12(5), 3410-3417.

[64] Nikam Nikita, R., Vaishnavi, A., & Lalchand, D. (2023). Parenteral drug delivery approach: an overview. Journal of xidian university, 17(1), 386-400.

[65] Shende, S. M., Meshram, B., Karemore, H., & Devhare, L. D. (2023). Development And Characterization of Glycerogelatin Suppositories For Enhanced Efficacy. European Journal of Pharmaceutical and Medical Research, 10(6), 522-528.

[66] Shukla, M., Tiware, S. A., Desai, S. R., Kumbhar, S. T., Khan, M. S., Mavai, Y., & Devhare, L. D. (2023). Pharmacological Evaluation of Gloriosa Superba Linn Flower Extract For Antiulcer Activity. Journal of Survey in Fisheries Sciences, 10(2), 463-470.

[67] Tiwari, R., Mishra, J., Devhare, L. D., & Tiwari, G. (2023). AN UPDATED REVIEW ON RECENT DEVELOPMENTS AND APPLI-CATIONS OF FISH COLLAGEN. Pharma Times, 55(06), 28.

[68] Polireddy, P., Malviya, V., Arora, S., Singh, M., pooja Tanaji, G., Devhare, L. D., & Dharmamoorthy, G. (2023). Assessment of Hepatoprotective Potential of Ecbolium Linneanum Extract on Experimental Animals. Journal of Coastal Life Medicine, 11, 884-890.

[69] Devhare, L. D., Kumbhar, S. T., Chitrapu, P., Kundral, S., & Borkar, A. A. (2023). In-Silico Molecular Docking Study of Substituted Imidazo 1, 3, 4 Thiadiazole Derivatives: Synthesis, Characterization, and Investigation of their Anti-Cancer Activity. Journal of Coastal Life Medicine, 11, 1237-1245.

[70] Sonule, M., Devhare, L. D., Babu, M. N., Gunjal, S. D., & Varalaxmi, S. (2023). Microemulgel-based Hydrogel of Diclofenac Sodium using Lipidium sativum as a Gelling Agent. International Journal of Drug Delivery Technology, 13(4), 1235-1239.

[71] Shriram, B. K., Devhare, L. D., Mehrotra, A., Deokar, S. S., & Singh, S. P. (2023). Formulation and Evaluation of Mosquito Repellent Stick. International Journal of Drug Delivery Technology, 13(4), 1283-1286.

[72] Tiwari, G., Gupta, M., Devhare, L. D., & Tiwari, R. (2024). Therapeutic and phytochemical properties of thymoquinone derived from Nigella sativa. Current Drug Research Reviews Formerly: Current Drug Abuse Reviews, 16(2), 145-156.

[73] Singh, M., Malik, A., Devhare, D. L., Ruikar, D. B., Krishnan, K., Kumar, D. V., & Devnani, D. (2023). Comparative Case Study On Tuberculosis Patients Between Rural And Urban Areas. Journal of Survey in Fisheries Sciences, 10(2), 1-11.

[74] Thakre, S. M., Kumar, D. V., Ahuja, A., Hamid, N., Thakre, A. R., Khan, M. S., & Devhare, L. (2023). Exploring the Influence of an Antifungal Medication on Patients Receiving Oral Hypoglycemic Therapy: Investigating the Interplay Between Medications. Journal of Coastal Life Medicine, 11, 1255-1262.

[75] Adimulapu, A. K., Devhare, L. D., Patil, A., Chachda, N. O., & Dharmamoorthy, G. (2023). Design and Development of Novel Mini Tablet Cap Technology for the Treatment of Cardiovascular Diseases. International Journal of Drug Delivery. Technology, 13(3), 801-806.

[76] Krishna, K. V., Jain, P. K., Devhare, L. D., Sharma, R. K., Bagade, O. M., Venkatesham, A., & Yogesh, P. K. (2023). A Study on Antidiabetic Potential of Dried Fruits Extract of Eucalyptus Globulus in Experimental Animals. Journal of Biomedical Engineering, 40(3), 99-110.

[77] Priya, M. G. R., Prasanth, L. M. L., Devhare, L. D., Yazdan, S. K., & Gunjal, S. (2024). Synthesis, DNA Binding, Molecular Docking and Anticancer Studies of Copper (II), Nickel (II), and Zinc (II) Complexes of Primaquine-based Ligand. International Journal of Pharmaceutical Quality Assurance, 15(1), 69-75.

[78] Choudhary, R. K., Beeraka, S., Sarkar, B. K., Dharmamoorthy, G., & Devhare, L. (2024). Optimizing Verapamil Hydrochloride In-situ Delivery: A Strategic Formulation Approach using Box-Behnken Design for Enhanced Performance and Comprehensive Evaluation of Formulation Parameters. International Journal of Drug Delivery Technology, 14(1), 61-70.

[79] Kumar, K. K., Kiran, V., Choudhary, R. K., Devhare, L. D., & Gunjal, S. D. (2024). Design Development and Characterization of Nicardipine Solid Lipid Nano-Particulars. International Journal of Drug Delivery Technology, 14(1), 71-78.

[80] Devhare, L. D., & Gokhale, N. (2023). Extraction. Phytochemical Screening and Comparative Pharmacological Evaluation of Some Indigenous Plants for Antiulcer Activity, 01-244.

[81] Devhare, L. D., Naikwadi, A. S., & Arote, S. B. (2023). Aditya V, Hiteshkumar S. Agrawal. Pharmacy Practice. Pritam Publication, 1-200.

[82] Devhare, L. D., & Nikam, N. (2023). Practical Handbook of Pharmacology-II. Pritam Publication, 1, 1-95.

[83] Devhare, L., & Prasad, C. (2024). Prophylactic and curative activity of Withania somnifera on experimentally induced calcium oxalate nephrolithiasis. Journal of medical pharmaceutical and allied sciences, 13(4), 6687-6695.

[84] Shende, S., Devhare, L., Prasad, C., Khobragade, A., & Khapne, A. (2024). Next-Generation Drug Delivery Strategies for Personalized Healthcare. Pharmaceutical Research - Recent Advances and Trends, 2, 28-62

[85] Devnani, D., Prasad, K. K., Bongade, K., Verma, A., Choudhary, T., Posa, M. K., & Devhare, D. L. (2024). Case Study On Rubella Virus. Journal of Advanced Zoology, 45(2). 1133

[86] Lalchand D. Devhare, Ram Kumar Choudhary, Kiran Kumar Kurella, Falgunee Dasharath Ghadi, Jyoti Mundlia, Murali Krishna Kandukuri. (2024). Research Methodology and Biostatistics.IIP Publication.1-165

[87] Kumar, Y. G., Dharmamoorthy, G., Devhare, L. D., Gunjal, S. D., & Deshpande, M. (2023). Toxicity Profile Study of Antihypertensive Drug Prazosin in Pregnant Wistar Rats. Journal of Advanced Zoology, 44, 64

[88] Devhare, L. D.(2023) Extraction phytochemical screening and comparative pharmacological evaluation of some indigenous plants for antiulcer activity.Shodhganga.1-244

[89] Konda V V S Krishna, Virendra Kumar Maurya, S. R. Fulmali, Praful N Giradkar, Lalchand D. Devhare (2023). A Textbook of Social and Preventive Pharmacy. Pritam Publication.1-201

[90] Konda V V S Krishna, Amruta R. Patil, Anupama A. Kapadnis, Vinod M. Thakare, Lalchand D. Devhare. (2023). Textbook of Pharmacotherapeutics. Pritam Publication.1-166

[91] Savita Shrikant Deokar Vedanshu R. Malviya, Biresh Kumar Sarkar, Lalchand D Devhare, Mangla Nand Singh.(2023). A Textbook of Novel Drug Delivery System. IIP Publication.1-230.

[92] Chand, G., Devhare, L. D., & Hooda, T. (2024). Diverse Properties of Tinospora Cordifolia (Giloy, Heart Leaved Moonseed) world wild use for immunotherapies;boosting the body's defence and immune support . Emerging Paradigms for Antibiotic-Resistant Infections: Beyond the Pill. Sringer Nature. 471-486

[93] Upreti, P., Devhare, L. D., Abdulmageed, L. H., Kumar, Y. G., Kumar, R., & Dharmamoorthy, G. (2024). Combatting Antibiotic Resistance: Leveraging Fecal Microbial transplantation for gut health. Emerging Paradigms for Antibiotic-Resistant Infections: Beyond the Pill. 211-232.

[94] Chandani Prasad, Lalchand Devhare, Ashish Khobragade and Shubham Shende. (2025). Herbal Approaches To Skin Lightening: A Comprehensive Review. 16(1): 62-68.

[95] Vyas S, Anitha KN, Mudduluru NB, Devhare LD. Quality by Design Approach to Nasal Mucoadhesive Microspheres: Enhanced Sumatriptan Succinate Delivery through Formulation and Characterization. International Journal of Drug Delivery Technology. 2024;14(3):1644-1651.